These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 29459143)

  • 1. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
    Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
    Winthrop KL; Mariette X; Silva JT; Benamu E; Calabrese LH; Dumusc A; Smolen JS; Aguado JM; Fernández-Ruiz M
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S21-S40. PubMed ID: 29447987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).
    Drgona L; Gudiol C; Lanini S; Salzberger B; Ippolito G; Mikulska M
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S83-S94. PubMed ID: 29572070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52).
    Mikulska M; Lanini S; Gudiol C; Drgona L; Ippolito G; Fernández-Ruiz M; Salzberger B
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S71-S82. PubMed ID: 29447988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
    Redelman-Sidi G; Michielin O; Cervera C; Ribi C; Aguado JM; Fernández-Ruiz M; Manuel O
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2(Suppl 2):S95-S107. PubMed ID: 29427804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways).
    Aguilar-Company J; Fernández-Ruiz M; García-Campelo R; Garrido-Castro AC; Ruiz-Camps I
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S41-S52. PubMed ID: 29426804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
    Reinwald M; Silva JT; Mueller NJ; Fortún J; Garzoni C; de Fijter JW; Fernández-Ruiz M; Grossi P; Aguado JM
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S53-S70. PubMed ID: 29454849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction).
    Fernández-Ruiz M; Meije Y; Manuel O; Akan H; Carratalà J; Aguado JM; Delaloye J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S2-S9. PubMed ID: 29427801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial for ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective.
    Aguado JM; Manuel O
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S1. PubMed ID: 29803289
    [No Abstract]   [Full Text] [Related]  

  • 11. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.
    Tragiannidis A; Kyriakidis I; Zündorf I; Groll AH
    Mycoses; 2017 Apr; 60(4):222-229. PubMed ID: 27766695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases.
    Pérez-Alvarez R; Díaz-Lagares C; García-Hernández F; Lopez-Roses L; Brito-Zerón P; Pérez-de-Lis M; Retamozo S; Bové A; Bosch X; Sanchez-Tapias JM; Forns X; Ramos-Casals M;
    Medicine (Baltimore); 2011 Nov; 90(6):359-371. PubMed ID: 22033451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.
    Downey C
    Int J Rheum Dis; 2016 Jun; 19(6):536-50. PubMed ID: 26200188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.
    Carroll MB; Forgione MA
    Clin Rheumatol; 2010 Sep; 29(9):1021-9. PubMed ID: 20556450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    J Gastroenterol Hepatol; 2018 Jan; 33(1):20-29. PubMed ID: 29023903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection risk associated with anti-TNF-α agents: a review.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
    Expert Opin Drug Saf; 2015 Apr; 14(4):571-82. PubMed ID: 25630559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.